Biolyst › PVLAPALVELLA THERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 31, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 69.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.
Track PVLA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PVLA in the tracker
Recent history
Date Event Type Phase
August 4, 2026
Quarterly results filed (8-K) Earnings
—
July 14, 2026
8-K filed: Other event Filing
—
June 30, 2026
8-K filed: Leadership change Corporate
—
June 16, 2026
8-K filed: Leadership change Corporate
—
May 20, 2026
8-K filed: Other event Filing
—
May 15, 2026
8-K filed: Other event Filing
—
May 13, 2026
8-K filed: Other event Filing
—
May 7, 2026
Quarterly results filed (8-K) Earnings
—
April 13, 2026
8-K filed: Leadership change Corporate
—
April 7, 2026
8-K filed: Other event Filing
—
March 31, 2026
Quarterly results filed (8-K) Earnings
—
February 26, 2026
8-K filed: Material agreement Corporate
—
February 24, 2026
8-K filed: Other event Filing
—
February 24, 2026
8-K filed: Reg FD disclosure Filing
—
February 24, 2026
Quarterly results filed (8-K) Earnings
—
January 29, 2026
8-K filed: Other event Filing
—
January 14, 2026
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations Trial Milestone
Phase 3
January 12, 2026
8-K filed: Other event Filing
—
December 15, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
November 21, 2025
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations Trial Milestone
Phase 2
November 10, 2025
Quarterly results filed (8-K) Earnings
—
November 5, 2025
8-K filed: Reg FD disclosure, Other event Filing
—
September 24, 2025
8-K filed: Reg FD disclosure Filing
—
September 3, 2025
8-K filed: Reg FD disclosure Filing
—
August 14, 2025
Quarterly results filed (8-K) Earnings
—
May 15, 2025
Quarterly results filed (8-K) Earnings
—
October 15, 2023
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita Trial Milestone
Phase 3
June 30, 2023
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita Trial Milestone
Phase 3
March 13, 2023
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome Trial Milestone
Phase 2
November 15, 2022
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations Trial Milestone
Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.